Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2015-02-22 Director's Dealing
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notices 8 pages 1.4MB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in directors' relevant interests in securities, including the number of shares held before and after the change, the nature of the change, and consideration paid. The document is a formal notification to the ASX about directors' personal share transactions. It does not contain financial statements, management discussion, or other report content. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is substantial and contains multiple such notices for different directors, confirming it is not a brief announcement but a detailed insider trading report.
2015-02-22 English
Appendix 3B 9 pages 348.1KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, including fully paid ordinary shares, options, and an entitlement offer. It details the number of securities issued, issue prices, purposes of the issue, underwriting fees, and dates related to the securities issuance and quotation on the ASX (Australian Securities Exchange). The document includes terms of the securities, underwriting details, and a quotation agreement with ASX. There is no financial performance data, earnings information, or management discussion. The content is focused on capital raising activities and the issuance of new shares and options. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is substantial (over 14,000 characters), indicating it is the announcement itself, not a brief notice or report publication announcement. Therefore, the correct classification is CAP with high confidence.
2015-02-19 English
Section 708A notice 1 page 259.3KB
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) regarding the issuance of fully paid ordinary shares by Mayne Pharma Group Limited. It states compliance with disclosure requirements and confirms no excluded information. The document is short (1804 characters) and serves as a formal regulatory announcement about a share placement without disclosure under Part 6D.2 of the Corporations Act. It does not contain financial statements or detailed financial data, nor is it a report or presentation. This fits the category of a Regulatory Filing (RNS), as it is a compliance notice related to capital raising but not a full capital/financing update report.
2015-02-19 English
Retail Offer Booklet 56 pages 6.0MB
Capital/Financing Update Classification · 95% confidence The document is titled 'Retail Entitlement Offer' and details a fully underwritten non-renounceable retail entitlement offer by Mayne Pharma Group Limited. It includes information about the offer terms, key dates, chairman's letter, and details about the equity raising and acquisitions funding. The document is dated February 2015 and is clearly an offer document related to a capital raising event. It is not a financial report, earnings release, or management discussion. It is a detailed announcement and offer document for a capital raising via an entitlement offer. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the offer document itself, not just an announcement of a report. Hence, the classification is CAP with high confidence.
2015-02-17 English
Entitlement Offer - Notification to ineligible shareholders 3 pages 343.1KB
Capital/Financing Update Classification · 95% confidence The document is a letter dated 18 February 2015 from Mayne Pharma Group Limited to shareholders informing them about an entitlement offer and specifically notifying ineligible shareholders that they cannot participate. It details the terms of the entitlement offer, eligibility criteria, and legal disclaimers. The content focuses on a capital raising event (entitlement offer and placement) and the procedural notice to shareholders who are not eligible to participate. There are no financial statements or detailed financial analysis included, only an announcement and explanation of the capital raising event and shareholder eligibility. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising activities and capital structure changes.
2015-02-17 English
Completion institutional entitlement offer and placement 2 pages 430.5KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 12 February 2015 from Mayne Pharma Group Limited regarding the successful completion of an institutional entitlement offer and placement, raising approximately A$71.8 million. It details the equity raising, pricing, shareholder participation, and upcoming retail entitlement offer dates. The content focuses on fundraising activities and capital structure changes, with no financial statements or detailed financial performance data included. The document is about a capital raising event and placement, which fits the Capital/Financing Update category. The document length is 6045 characters, sufficient to provide substantive information about the capital raising but not a full financial report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2015-02-11 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.